Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 [Yahoo! Finance]
Climb Bio, Inc. (CLYM)
Company Research
Source: Yahoo! Finance
2026 and initial clinical readouts for PMN, ITP and SLE in H2 2026, while healthy-volunteer data for CLYM116 is expected around midyear. Budoprutug is a CD19 monoclonal being developed as a subcutaneous B-cell depleter targeting PMN, ITP and SLE; the program emphasizes biomarker and B-cell depletion readouts and is positioned as a broader/ repeatable alternative to CD20 therapies. CLYM116 is an APRIL-only “sweeper” antibody with pH-dependent binding and FcRn recycling that showed up to ~80% IgA reduction in NHPs; mid-2026 healthy-volunteer data will assess PK, IgA lowering and immunogenicity as the company targets IgA nephropathy. Interested in Climb Bio, Inc.? Here are five stocks we like better. Climb Bio (NASDAQ:CLYM) used a presentation at the Leerink Partners Global Healthcare Conference to outline its strategy around two immune-focused programs and to preview a series of data readouts expected in 2026. Chief Executive Officer Aoife Brennan and Chief Financial Officer Sus
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio (CLYM) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Climb Bio (CLYM) was given a new $17.00 price target by Truist Financial Corporation.MarketBeat
- Climb Bio (CLYM) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.MarketBeat
- Climb Bio (CLYM) had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Climb Bio (CLYM) had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
CLYM
Earnings
- 3/25/25 - Beat
CLYM
Sec Filings
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- CLYM's page on the SEC website